2026-10-19T01:18:24Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/148472026-10-18T21:14:24Zopenairedrivercom_ebyu_10000col_ebyu_10001

Design of potent fluoro-substituted chalcones as antimicrobial agentsBurmaoglu, SerdarAlgul, OztekinGobek, ArzuAktas Anil, DeryaUlger, MahmutErturk, Busra GulKaplan, EnginDogen, AylinAslan, Gönülantimicrobial activityantitubercular activityChalconeSARAnti-Infective AgentsChalconesFluorineMicrobial Sensitivity TestsMycobacterium tuberculosisStructure-Activity Relationshipampicillinantiinfective agentchalcone derivativefluconazoletuberculostatic agentantifungal activityArticlecontrolled studydrug designdrug efficacydrug synthesisIC50minimum inhibitory concentrationnonhumanpriority journalstructure activity relationsubstitution reactionchemistrydrug effectsmicrobial sensitivity testOwing to ever-increasing bacterial and fungal drug resistance, we attempted to develop novel antitubercular and antimicrobial agents. For this purpose, we developed some new fluorine-substituted chalcone analogs (3, 4, 9–15, and 20–23) using a structure–activity relationship approach. Target compounds were evaluated for their antitubercular efficacy against Mycobacterium tuberculosis H37Rv and antimicrobial activity against five common pathogenic bacterial and three common fungal strains. Three derivatives (3, 9, and 10) displayed significant antitubercular activity with IC50 values of ≤16,760. Compounds derived from trimethoxy substituent scaffolds with monofluoro substitution on the B ring of the chalcone structure exhibited superior inhibition activity compared to corresponding hydroxy analogs. In terms of antimicrobial activity, most compounds (3, 9, 12–14, and 23) exhibited moderate to potent activity against the bacteria, and the antifungal activities of compounds 3, 13, 15, 20, and 22 were comparable to those of reference drugs ampicillin and fluconazole. © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Taylor and Francis Ltd2017Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/14847https://doi.org/10.1080/14756366.2016.12655171475-6366enJournal of Enzyme Inhibition and Medicinal Chemistryinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14847